Craft

GemVax & KAEL

Stock Price

₩13.7 K

2024-10-29

Market Capitalization

₩521.8 B

2024-10-29

Revenue

₩81.5 B

FY, 2025

GemVax & KAEL Summary

Company Summary

Overview
GemVax & KAEL (젬백스앤카엘) is a company that focuses on the manufacturing of coating resins and filters for semiconductors as well as panel display production. It is also engaged in the research and development of anticancer drugs. The company manufactures and supplies RIAVAX, an immunotherapeutic peptide for the treatment of locally advanced or metastatic pancreatic cancer patients.
Type
Public
Status
Active
Founded
1998
HQ
KR | view all locations
Website
http://www.gemvax.com
Cybersecurity rating
ESG rating
40-49 out of 100|View all ESG data
Sectors

Key People

  • Kim Sang-Jae, Chief Executive Officer

    LocationsView all

    1 location detected

    • Daejeon HQ

      Korea (Republic of)

      58 Techno 11-ro, Yuseong-gu

    GemVax & KAEL Financials

    Summary Financials

    Revenue (FY, 2025)
    ₩81.5B
    Gross profit (FY, 2025)
    ₩37.8B
    Net income (FY, 2025)
    (₩11.3B)
    Cash (FY, 2025)
    ₩17.6B
    EBIT (FY, 2025)
    (₩4.6B)
    Enterprise value
    $562.3B

    Footer menu